NCODA Logo

The purpose of this PQI is to provide information on the use of vorasidenib (Voranigo®) in the treatment of isocitrate dehydrogenase mutant, low-grade glioma, as well as discuss clinical pearls to enhance appropriate patient selection, monitoring, and follow-up.